|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shawki S, Ashburn J, Signs SA and Huang E:
Colon cancer: Inflammation-associated cancer. Surg Oncol Clin N Am.
27:269–287. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu C: Systemic therapy for colon cancer.
Surg Oncol Clin N Am. 27:235–242. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mody K and Bekaii-Saab T: Clinical trials
and progress in metastatic colon cancer. Surg Oncol Clin N Am.
27:349–365. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bao X, Zhang H, Wu W, Cheng S, Dai X, Zhu
X, Fu Q, Tong Z, Liu L, Zheng Y, et al: Analysis of the molecular
nature associated with microsatellite status in colon cancer
identifies clinical implications for immunotherapy. J Immunother
Cancer. 8:e0014372020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ruan H, Leibowitz BJ, Zhang L and Yu J:
Immunogenic cell death in colon cancer prevention and therapy. Mol
Carcinog. 59:783–793. 2020. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lichtenstern CR, Ngu RK, Shalapour S and
Karin M: Immunotherapy, inflammation and colorectal cancer. Cells.
9:6182020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Katoh M: GIPC gene family (review). Int J
Mol Med. 9:585–589. 2002.PubMed/NCBI
|
|
9
|
Katoh M: Functional proteomics, human
genetics and cancer biology of GIPC family members. Exp Mol Med.
45:e262013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saitoh T, Mine T and Katoh M: Molecular
cloning and characterization of human GIPC3, a novel gene
homologous to human GIPC1 and GIPC2. Int J Oncol. 20:577–582.
2002.PubMed/NCBI
|
|
11
|
De Marco N, Tussellino M, Carotenuto R,
Ronca R, Rizzolio S, Biffo S and Campanella C: Eukaryotic
initiation factor eIF6 modulates the expression of Kermit 2/XGIPC
in IGF-regulated eye development. Dev Biol. 427:148–154. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tussellino M, De Marco N, Campanella C and
Carotenuto R: Involvement of the eukaryotic initiation factor 6 and
kermit2/gipc2 in Xenopus laevis pronephros formation. Int J Dev
Biol. 56:357–362. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Comijn J, Berx G, Vermassen P, Verschueren
K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D and van Roy
F: The two-handed E box binding zinc finger protein SIP1
downregulates E-cadherin and induces invasion. Mol Cell.
7:1267–1278. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang LH, Kalb RG and Strittmatter SM: A
PDZ protein regulates the distribution of the transmembrane
semaphorin, M-SemF. J Biol Chem. 274:14137–14146. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang C, He Y, You Z and Chen X: TMSB10
promotes progression of clear cell renal cell carcinoma via JUN
transcription regulation. Ann Clin Lab Sci. 52:230–239.
2022.PubMed/NCBI
|
|
16
|
Peng W, Li W, Zhang X, Cen W and Liu Y:
The intercorrelation among CCT6A, CDC20, CCNB1, and PLK1
expressions and their clinical value in papillary thyroid carcinoma
prognostication. J Clin Lab Anal. 36:e246092022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sturm G, Finotello F, Petitprez F, Zhang
JD, Baumbach J, Fridman WH, List M and Aneichyk T: Comprehensive
evaluation of transcriptome-based cell-type quantification methods
for immuno-oncology. Bioinformatics. 35:i436–i445. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
R Core Team, . R: A language and
environment for statistical computing. R Foundation for Statistical
Computing; Vienna, Austria: 2020, https://www.r-project.org/
|
|
19
|
Kirikoshi H and Katoh M: Up-regulation of
GIPC2 in human gastric cancer. Int J Oncol. 20:1183–1187.
2020.PubMed/NCBI
|
|
20
|
Wang L, Wang J, Yin X, Guan X, Li Y, Xin C
and Liu J: GIPC2 interacts with Fzd7 to promote prostate cancer
metastasis by activating WNT signaling. Oncogene. 41:2609–2623.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu Z, Wan Y, Yang M, Qi X, Dong Z, Huang
J and Xu J: Identification of methylation-driven genes related to
the prognosis of papillary renal cell carcinoma: A study based on
the cancer genome atlas. Cancer Cell Int. 20:2352020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dong Y, Huang Y, Fan C, Wang L, Zhang R,
Li W, Guo Z, Wang D and Zheng Z: GIPC2 is an endocrine-specific
tumor suppressor gene for both sporadic and hereditary tumors of
RET- and SDHB-, but not VHL-associated clusters of
pheochromocytoma/paraganglioma. Cell Death Dis. 12:4442021.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu X and Fuentes EJ: Emerging themes in
PDZ domain signaling: Structure, function, and inhibition. Int Rev
Cell Mol Biol. 343:129–218. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Khan Z and Lafon M: PDZ domain-mediated
protein interactions: Therapeutic targets in neurological
disorders. Curr Med Chem. 21:2632–2641. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tso PH, Wang Y, Wong SY, Poon LS, Chan AS
and Wong YH: RGS19 enhances cell proliferation through its
C-terminal PDZ motif. Cell Signal. 22:1700–1707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu Y, Lou W, Chen G, Ding B, Kuang J,
Zhang Y, Wang C, Duan S, Deng Y and Lu X: Genome-wide screening for
the G-protein-coupled receptor (GPCR) pathway-related therapeutic
gene RGS19 (regulator of G protein signaling 19) in bladder cancer.
Bioengineered. 12:5892–5903. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ji YR, Kim MO, Kim SH, Yu DH, Shin MJ, Kim
HJ, Yuh HS, Bae KB, Kim JY, Park HD, et al: Effects of regulator of
G protein signaling 19 (RGS19) on heart development and function. J
Biol Chem. 285:28627–28634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cancer Genome Atlas Research Network, .
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Berger MF, Hodis E, Heffernan TP, Deribe
YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E,
Ghosh P, et al: Melanoma genome sequencing reveals frequent PREX2
mutations. Nature. 485:502–506. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cancer Genome Atlas Network, .
Comprehensive molecular characterization of human colon and rectal
cancer. Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
McGowan CH: Checking in on Cds1 (Chk2): A
checkpoint kinase and tumor suppressor. Bioessays. 24:502–511.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li S, Ma J, Si Y, Cheng S, Hu M, Zhi X, Li
B, Yu H and Jiang WG: Differential expression and functions of Ehm2
transcript variants in lung adenocarcinoma. Int J Oncol.
54:1747–1758. 2019.PubMed/NCBI
|
|
33
|
Quan J, Bode AM and Luo X: ACSL family:
The regulatory mechanisms and therapeutic implications in cancer.
Eur J Pharmacol. 909:1743972021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ma W, Li T, Wu S, Li J, Wang X and Li H:
LOX and ACSL5 as potential relapse markers for pancreatic cancer
patients. Cancer Biol Ther. 20:787–798. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hartmann F, Sparla D, Tute E, Tamm M,
Schneider U, Jeon MK, Kasperk R, Gassler N and Kaemmerer E: Low
acyl-CoA synthetase 5 expression in colorectal carcinomas is
prognostic for early tumour recurrence. Pathol Res Pract.
213:261–266. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jeanneteau F, Guillin O, Diaz J, Griffon N
and Sokoloff P: GIPC recruits GAIP (RGS19) to attenuate dopamine D2
receptor signaling. Mol Biol Cell. 15:4926–4937. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ding X, Philip S, Martin BK, Pang Y,
Burkett S, Swing DA, Pamala C, Ritt DA, Zhou M, Morrison DK, et al:
Survival of BRCA2-deficient cells is promoted by GIPC3, a novel
genetic interactor of BRCA2. Genetics. 207:1335–1345. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Williams GH and Stoeber K: The cell cycle
and cancer. J Pathol. 226:352–364. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Topalian SL, Taube JM, Anders RA and
Pardoll DM: Mechanism-driven biomarkers to guide immune checkpoint
blockade in cancer therapy. Nat Rev Cancer. 16:275–287. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Galluzzi L, Humeau J, Buqué A, Zitvogel L
and Kroemer G: Immunostimulation with chemotherapy in the era of
immune checkpoint inhibitors. Nat Rev Clin Oncol. 17:725–741. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Funes SC, Manrique de Lara A,
Altamirano-Lagos MJ, Mackern-Oberti JP, Escobar-Vera J and Kalergis
AM: Immune checkpoints and the regulation of tolerogenicity in
dendritic cells: Implications for autoimmunity and immunotherapy.
Autoimmun Rev. 18:359–368. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang Y and Zheng J: Functions of immune
checkpoint molecules beyond immune evasion. Adv Exp Med Biol.
1248:201–226. 2020. View Article : Google Scholar : PubMed/NCBI
|
